

Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Growth 2023-2029

https://marketpublishers.com/r/G27581C75368EN.html

Date: August 2023

Pages: 129

Price: US\$ 3,660.00 (Single User License)

ID: G27581C75368EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our (LP Info Research) latest study, the global Paroxysmal Nocturnal Hemoglobinuria Drug market size was valued at US\$ 3130.4 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Paroxysmal Nocturnal Hemoglobinuria Drug is forecast to a readjusted size of US\$ 7589.1 million by 2029 with a CAGR of 13.5% during review period.

The research report highlights the growth potential of the global Paroxysmal Nocturnal Hemoglobinuria Drug market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Paroxysmal Nocturnal Hemoglobinuria Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Paroxysmal Nocturnal Hemoglobinuria Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Paroxysmal Nocturnal Hemoglobinuria Drug market.

Key Features:

The report on Paroxysmal Nocturnal Hemoglobinuria Drug market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Paroxysmal Nocturnal Hemoglobinuria Drug market. It may include



historical data, market segmentation by Type (e.g., Eculizumab, Ravulizumab), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Paroxysmal Nocturnal Hemoglobinuria Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Paroxysmal Nocturnal Hemoglobinuria Drug industry. This include advancements in Paroxysmal Nocturnal Hemoglobinuria Drug technology, Paroxysmal Nocturnal Hemoglobinuria Drug new entrants, Paroxysmal Nocturnal Hemoglobinuria Drug new investment, and other innovations that are shaping the future of Paroxysmal Nocturnal Hemoglobinuria Drug.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes factors influencing customer 'purchasing decisions, preferences for Paroxysmal Nocturnal Hemoglobinuria Drug product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Paroxysmal Nocturnal Hemoglobinuria Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Paroxysmal Nocturnal Hemoglobinuria Drug market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Paroxysmal Nocturnal Hemoglobinuria Drug market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Paroxysmal Nocturnal




Hemoglobinuria Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Paroxysmal Nocturnal Hemoglobinuria Drug market.

Market Segmentation:

Paroxysmal Nocturnal Hemoglobinuria Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.



This report also splits the market by region:

Americas



		United States
		Canada
		Mexico
		Brazil
	APAC	
		China
		Japan
		Korea
		Southeast Asia
		India
		Australia
Europe		е
		Germany
		France
		UK
		Italy
		Russia
Middle East & Africa		
		Egypt

South Africa



Israel

Turkey	
GCC Countries	
The below companies that are profiled have been selected based on inputs gathere from primary experts and analyzing the company's coverage, product portfolio, its market penetration.	
Apellis Pharmaceuticals	
Alexion Pharmaceuticals Inc	
Akari Therapeutics Plc	
CinnaGen Co	
Ra Pharmaceuticals Inc	
Amgen Inc	
Achillion Pharmaceuticals Inc	
Alnylam Pharmaceuticals Inc	
F. Hoffmann-La Roche Ltd	
Novartis AG	
Regeneron Pharmaceuticals Inc	
BIOCAD	
Samsung Bioepis	
Amyndas Pharmaceuticals	



Teva Pharmaceutical Industries Ltd.			
LGM Pharma.			
Lannett			
NorthStar Rx LLC			
Abbott			
Par Pharmaceutical			
Key Questions Addressed in this Report			
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria Drug market?			
What factors are driving Paroxysmal Nocturnal Hemoglobinuria Drug market growth, globally and by region?			
Which technologies are poised for the fastest growth by market and region?			
How do Paroxysmal Nocturnal Hemoglobinuria Drug market opportunities vary by end market size?			
How does Paroxysmal Nocturnal Hemoglobinuria Drug break out type, application?			
What are the influences of COVID-19 and Russia-Ukraine war?			



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria Drug by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria Drug by Country/Region, 2018, 2022 & 2029
- 2.2 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Type
 - 2.2.1 Eculizumab
 - 2.2.2 Ravulizumab
 - 2.2.3 Others
- 2.3 Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
- 2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
- 2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Type (2018-2023)
- 2.4 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Application
 - 2.4.1 Clinic
 - 2.4.2 Hospital
 - 2.4.3 Others
- 2.5 Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
- 2.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Market Share by Application (2018-2023)



- 2.5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Application (2018-2023)

3 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY COMPANY

- 3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Breakdown Data by Company
- 3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Company (2018-2023)
- 3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company (2018-2023)
- 3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Company (2018-2023)
- 3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Company (2018-2023)
- 3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company (2018-2023)
- 3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Company
- 3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Product Location Distribution
- 3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria Drug Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY GEOGRAPHIC REGION

- 4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Geographic Region (2018-2023)
- 4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Geographic Region (2018-2023)



- 4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country/Region (2018-2023)
- 4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
- 4.4 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
- 4.5 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
- 4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth

5 AMERICAS

- 5.1 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country
- 5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
- 5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
- 5.2 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
- 5.3 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
- 6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018-2023)
- 6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2018-2023)
- 6.2 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
- 6.3 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia



6.10 China Taiwan

7 EUROPE

- 7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug by Country
- 7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
- 7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
- 7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
- 7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug by Country
- 8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
- 8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends



10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
- 10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
- 10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors
- 11.3 Paroxysmal Nocturnal Hemoglobinuria Drug Customer

12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY GEOGRAPHIC REGION

- 12.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Region
- 12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Region (2024-2029)
- 12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Type
- 12.7 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Apellis Pharmaceuticals
 - 13.1.1 Apellis Pharmaceuticals Company Information
- 13.1.2 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
 - 13.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales,



- Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Apellis Pharmaceuticals Main Business Overview
- 13.1.5 Apellis Pharmaceuticals Latest Developments
- 13.2 Alexion Pharmaceuticals Inc
 - 13.2.1 Alexion Pharmaceuticals Inc Company Information
- 13.2.2 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Alexion Pharmaceuticals Inc Main Business Overview
- 13.2.5 Alexion Pharmaceuticals Inc Latest Developments
- 13.3 Akari Therapeutics Plc
 - 13.3.1 Akari Therapeutics Plc Company Information
- 13.3.2 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Akari Therapeutics Plc Main Business Overview
 - 13.3.5 Akari Therapeutics Plc Latest Developments
- 13.4 CinnaGen Co
 - 13.4.1 CinnaGen Co Company Information
- 13.4.2 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.4.4 CinnaGen Co Main Business Overview
 - 13.4.5 CinnaGen Co Latest Developments
- 13.5 Ra Pharmaceuticals Inc
 - 13.5.1 Ra Pharmaceuticals Inc Company Information
- 13.5.2 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Ra Pharmaceuticals Inc Main Business Overview
 - 13.5.5 Ra Pharmaceuticals Inc Latest Developments
- 13.6 Amgen Inc
 - 13.6.1 Amgen Inc Company Information
- 13.6.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications



- 13.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Amgen Inc Main Business Overview
 - 13.6.5 Amgen Inc Latest Developments
- 13.7 Achillion Pharmaceuticals Inc
 - 13.7.1 Achillion Pharmaceuticals Inc Company Information
- 13.7.2 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Achillion Pharmaceuticals Inc Main Business Overview
 - 13.7.5 Achillion Pharmaceuticals Inc Latest Developments
- 13.8 Alnylam Pharmaceuticals Inc
- 13.8.1 Alnylam Pharmaceuticals Inc Company Information
- 13.8.2 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Alnylam Pharmaceuticals Inc Main Business Overview
 - 13.8.5 Alnylam Pharmaceuticals Inc Latest Developments
- 13.9 F. Hoffmann-La Roche Ltd
 - 13.9.1 F. Hoffmann-La Roche Ltd Company Information
- 13.9.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 F. Hoffmann-La Roche Ltd Main Business Overview
 - 13.9.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.10 Novartis AG
 - 13.10.1 Novartis AG Company Information
- 13.10.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.10.4 Novartis AG Main Business Overview
 - 13.10.5 Novartis AG Latest Developments
- 13.11 Regeneron Pharmaceuticals Inc
- 13.11.1 Regeneron Pharmaceuticals Inc Company Information
- 13.11.2 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug



Product Portfolios and Specifications

- 13.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.11.4 Regeneron Pharmaceuticals Inc Main Business Overview
- 13.11.5 Regeneron Pharmaceuticals Inc Latest Developments
- **13.12 BIOCAD**
 - 13.12.1 BIOCAD Company Information
- 13.12.2 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.12.4 BIOCAD Main Business Overview
 - 13.12.5 BIOCAD Latest Developments
- 13.13 Samsung Bioepis
 - 13.13.1 Samsung Bioepis Company Information
- 13.13.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
 - 13.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales,

Revenue, Price and Gross Margin (2018-2023)

- 13.13.4 Samsung Bioepis Main Business Overview
- 13.13.5 Samsung Bioepis Latest Developments
- 13.14 Amyndas Pharmaceuticals
 - 13.14.1 Amyndas Pharmaceuticals Company Information
- 13.14.2 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug

Product Portfolios and Specifications

- 13.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.14.4 Amyndas Pharmaceuticals Main Business Overview
- 13.14.5 Amyndas Pharmaceuticals Latest Developments
- 13.15 Teva Pharmaceutical Industries Ltd.
 - 13.15.1 Teva Pharmaceutical Industries Ltd. Company Information
- 13.15.2 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.15.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
 - 13.15.5 Teva Pharmaceutical Industries Ltd. Latest Developments
- 13.16 LGM Pharma.
- 13.16.1 LGM Pharma. Company Information



- 13.16.2 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.16.4 LGM Pharma. Main Business Overview
- 13.16.5 LGM Pharma. Latest Developments
- 13.17 Lannett
 - 13.17.1 Lannett Company Information
- 13.17.2 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.17.4 Lannett Main Business Overview
 - 13.17.5 Lannett Latest Developments
- 13.18 NorthStar Rx LLC
 - 13.18.1 NorthStar Rx LLC Company Information
- 13.18.2 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.18.4 NorthStar Rx LLC Main Business Overview
 - 13.18.5 NorthStar Rx LLC Latest Developments
- 13.19 Abbott
 - 13.19.1 Abbott Company Information
- 13.19.2 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.19.4 Abbott Main Business Overview
 - 13.19.5 Abbott Latest Developments
- 13.20 Par Pharmaceutical
 - 13.20.1 Par Pharmaceutical Company Information
- 13.20.2 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- 13.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales,
- Revenue, Price and Gross Margin (2018-2023)
 - 13.20.4 Par Pharmaceutical Main Business Overview
 - 13.20.5 Par Pharmaceutical Latest Developments



14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

Table 1. Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Eculizumab

Table 4. Major Players of Ravulizumab

Table 5. Major Players of Others

Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)

Table 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)

Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2018-2023) & (\$ million)

Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2023)

Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Type (2018-2023) & (US\$/Unit)

Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)

Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)

Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2018-2023)

Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2018-2023)

Table 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Application (2018-2023) & (US\$/Unit)

Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Company (2018-2023) & (K Units)

Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company (2018-2023)

Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Company (2018-2023) (\$ Millions)

Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company (2018-2023)



- Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 21. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Producing Area Distribution and Sales Area
- Table 22. Players Paroxysmal Nocturnal Hemoglobinuria Drug Products Offered
- Table 23. Paroxysmal Nocturnal Hemoglobinuria Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Geographic Region (2018-2023) & (K Units)
- Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Geographic Region (2018-2023)
- Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Geographic Region (2018-2023)
- Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country/Region (2018-2023) & (K Units)
- Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country/Region (2018-2023)
- Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country/Region (2018-2023)
- Table 34. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
- Table 35. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
- Table 36. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & (\$ Millions)
- Table 37. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
- Table 38. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
- Table 39. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
- Table 40. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018-2023) & (K Units)



Table 41. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2018-2023)

Table 42. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2018-2023)

Table 44. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)

Table 45. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)

Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)

Table 47. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)

Table 48. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)

Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)

Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria Drug

Table 59. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria Drug

Table 60. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria Drug



- Table 61. Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material
- Table 62. Key Suppliers of Raw Materials
- Table 63. Paroxysmal Nocturnal Hemoglobinuria Drug Distributors List
- Table 64. Paroxysmal Nocturnal Hemoglobinuria Drug Customer List
- Table 65. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Region (2024-2029) & (K Units)
- Table 66. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 67. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
- Table 68. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 69. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Region (2024-2029) & (K Units)
- Table 70. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 71. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
- Table 72. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 73. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
- Table 74. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 75. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Type (2024-2029) & (K Units)
- Table 76. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 77. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Application (2024-2029) & (K Units)
- Table 78. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 79. Apellis Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
- Table 80. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
- Table 81. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 82. Apellis Pharmaceuticals Main Business



Table 83. Apellis Pharmaceuticals Latest Developments

Table 84. Alexion Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 85. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 86. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Alexion Pharmaceuticals Inc Main Business

Table 88. Alexion Pharmaceuticals Inc Latest Developments

Table 89. Akari Therapeutics Plc Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 90. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 91. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Akari Therapeutics Plc Main Business

Table 93. Akari Therapeutics Plc Latest Developments

Table 94. CinnaGen Co Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 96. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. CinnaGen Co Main Business

Table 98. CinnaGen Co Latest Developments

Table 99. Ra Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 101. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Ra Pharmaceuticals Inc Main Business

Table 103. Ra Pharmaceuticals Inc Latest Developments

Table 104. Amgen Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 106. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)



Table 107. Amgen Inc Main Business

Table 108. Amgen Inc Latest Developments

Table 109. Achillion Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 111. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. Achillion Pharmaceuticals Inc Main Business

Table 113. Achillion Pharmaceuticals Inc Latest Developments

Table 114. Alnylam Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 115. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 116. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. Alnylam Pharmaceuticals Inc Main Business

Table 118. Alnylam Pharmaceuticals Inc Latest Developments

Table 119. F. Hoffmann-La Roche Ltd Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 121. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. F. Hoffmann-La Roche Ltd Main Business

Table 123. F. Hoffmann-La Roche Ltd Latest Developments

Table 124. Novartis AG Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 125. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 126. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 127. Novartis AG Main Business

Table 128. Novartis AG Latest Developments

Table 129. Regeneron Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 130. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria

Drug Product Portfolios and Specifications

Table 131. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria



Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 132. Regeneron Pharmaceuticals Inc Main Business

Table 133. Regeneron Pharmaceuticals Inc Latest Developments

Table 134. BIOCAD Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 135. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 136. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 137. BIOCAD Main Business

Table 138. BIOCAD Latest Developments

Table 139. Samsung Bioepis Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 140. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 141. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 142. Samsung Bioepis Main Business

Table 143. Samsung Bioepis Latest Developments

Table 144. Amyndas Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 145. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 146. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 147. Amyndas Pharmaceuticals Main Business

Table 148. Amyndas Pharmaceuticals Latest Developments

Table 149. Teva Pharmaceutical Industries Ltd. Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors Table 150. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 151. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 152. Teva Pharmaceutical Industries Ltd. Main Business

Table 153. Teva Pharmaceutical Industries Ltd. Latest Developments

Table 154. LGM Pharma. Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors



Table 155. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 156. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 157. LGM Pharma. Main Business

Table 158. LGM Pharma. Latest Developments

Table 159. Lannett Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 160. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 161. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 162. Lannett Main Business

Table 163. Lannett Latest Developments

Table 164. NorthStar Rx LLC Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 165. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 166. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 167. NorthStar Rx LLC Main Business

Table 168. NorthStar Rx LLC Latest Developments

Table 169. Abbott Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 170. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 171. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 172. Abbott Main Business

Table 173. Abbott Latest Developments

Table 174. Par Pharmaceutical Basic Information, Paroxysmal Nocturnal

Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors

Table 175. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications

Table 176. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 177. Par Pharmaceutical Main Business

Table 178. Par Pharmaceutical Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria Drug
- Figure 2. Paroxysmal Nocturnal Hemoglobinuria Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Eculizumab
- Figure 10. Product Picture of Ravulizumab
- Figure 11. Product Picture of Others
- Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type in 2022
- Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2023)
- Figure 14. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Clinic
- Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Clinic (2018-2023) & (K Units)
- Figure 16. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Hospital
- Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Hospital (2018-2023) & (K Units)
- Figure 18. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Others
- Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Others (2018-2023) & (K Units)
- Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2022)
- Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application in 2022
- Figure 22. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market by Company in 2022 (K Units)
- Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company in 2022



- Figure 24. Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market by Company in 2022 (\$ Million)
- Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company in 2022
- Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Geographic Region (2018-2023)
- Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Geographic Region in 2022
- Figure 28. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
- Figure 29. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 (\$ Millions)
- Figure 30. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
- Figure 31. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 (\$ Millions)
- Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
- Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 (\$ Millions)
- Figure 34. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
- Figure 35. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 (\$ Millions)
- Figure 36. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
- Figure 37. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
- Figure 38. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
- Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
- Figure 40. United States Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 41. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 42. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 43. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth



2018-2023 (\$ Millions)

Figure 44. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region in 2022

Figure 45. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Regions in 2022

Figure 46. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)

Figure 47. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)

Figure 48. China Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022

Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022

Figure 57. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)

Figure 58. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)

Figure 59. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 60. France Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 61. UK Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)



Figure 63. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022

Figure 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022

Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)

Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)

Figure 68. Egypt Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 69. South Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Israel Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 72. GCC Country Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug in 2022

Figure 74. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug

Figure 75. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria Drug Figure 76. Channels of Distribution

Figure 77. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Forecast by Region (2024-2029)

Figure 78. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Region (2024-2029)

Figure 79. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Forecast by Type (2024-2029)

Figure 80. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Type (2024-2029)

Figure 81. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Forecast by Application (2024-2029)

Figure 82. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Application (2024-2029)



I would like to order

Product name: Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Growth 2023-2029

Product link: https://marketpublishers.com/r/G27581C75368EN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G27581C75368EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970